by Multiple Speakers,
One of the most significant hurdles facing the field of immuno-oncology is the limitation of technology’s ability to reveal the complex molecular machinery that regulates the tumor microenvironment in clinically-relevant specimens. Bringing new immune-targeted therapeutics to the clinic requires the ability to understand the mechanism of action as well as the co-development of companion diagnostics. Through new technological developments built on the well-established NanoString nCounter® platform, the simultaneous profiling of DNA, RNA, and protein in clinically-relevant samples is now readily achievable. NanoString has developed content and methods to allow digital quantification of both cell surface and intracellular protein targets that are essential to immuno-oncology research. Using the nCounter platform, it is now possible to simultaneously quantify 770 RNA transcripts plus 30 proteins from as few as 20,000 cells. Key targets include immune cell population markers, immune checkpoint proteins, transcription factors, chemokines, and cytokines. In this webinar, we will describe the development, validation and applications of this innovative multi-analyte technology. We will also describe how we have expanded this technology to provide spatial context to these molecular signatures within clinically-relevant specimens. Together, this new technology can accelerate immuno-oncology research to support the discovery and development of novel immunotherapies and their associated companion diagnostics.
6:00 - 7:00AM PST
9:00 - 10:00AM PST
Webinar Live during: Mar 08, 2017 at 6:00am
Gene expression signatures require both analytical and clinical validation, along with evidence of clinical utility, to be adopted into clinical practice as prognostic or predictive biomarkers. This webinar will focus on the aspects of analytical validation that are important for demonstrating that a gene expression signature is robust across a number of potential variables that may influence the accuracy or precision of the test. These variables include both pre-analytical variables such as sample collection and storage, as well as analytical variables such as RNA input amount or reagent lot. A recent case study of the Prosigna Breast Cancer Gene Signature Assay will be used as an example of how one may analytically characterize and subsequently validate a test.
6:00 - 7:00 am PST
9:00 - 10:00 am PST
Webinar Live during: Feb 28, 2017 at 6:00am
by Mireia Mato | Imperial College, London,
Many studies have identified a panel of microRNAs (miRNAs) that could discriminate healthy individuals from pancreatic cancer patients. However, there are just a few publications regarding miRNAs in bile.
The aim of this study was to detect pancreatic cancer at an early stage. Therefore, we used bile fluid because of its proximity to the malignant lesion and looked for miRNAs given their stability and resistance to degradation. RNA was isolated from 58 bile samples (benign n=14; chronic pancreatitis n=3; PDAC n=24; IPMN cancer n=8; cholangiocarcinoma n=6, and ampullary cancer n=3) and it was analyzed using nCounter® miRNA Expression Assay.
6:00 - 7:00am PST
9:00 - 10:00am PST
7:30 - 8:30am IST (India Standard Time)
10:00 - 11:00am CST (China Standard Time)
Webinar Live during: Dec 07, 2016 at 6:00am
by Gordon B. Mills , M.D., Ph.D.
NanoString is pioneering the field of 3D Biology to accelerate the rate of research and maximize the amount of information that can be generated from a given sample. 3D Biology is the ability to analyze combinations of DNA (detect SNVs and InDels), RNA (gene expression or fusion transcript detection), and protein (abundance and isoforms post-translational modifications) simultaneously on a single NanoString instrument system. This webinar will showcase the use of the new SNV Technology in detecting cancer driver mutations in a wide variety of FFPE samples, the utility of multiplexed DNA-labeled antibody approaches to quantify protein expression levels from small amounts of sample (both lysate and FFPE), and further present an upcoming 3D Biology application study model.
Webinar Live during: Nov 16, 2016 at 6:00am
by Joe Beechem, Ph.D.,
As the field of tumor biology research matures, the monitoring of multiple analyte types has become an increasingly important path towards understanding its complexities. To meet the need for multi-analyte profiling, NanoString Technologies has expanded its single-molecule barcoding system to recognize DNA, RNA, fusions, proteins and phospho-proteins simultaneously with our 3D Biology technology.
Detection of DNA, RNA, or proteins alone can provide significant information, but when data from multiple experiments are merged, from as few as two slices of FFPE, the integrated results can lead to novel hypotheses or more solid conclusions. Join our webinar to learn more about solid tumor profiling with NanoString 3D Biology technology utilizing Cell Signaling Technology antibodies.
November 2, 2016
November 3, 2016
7:30am IST (india)
10am CST (Beijing)
Webinar Live during: Nov 02, 2016 at 6:00am
by Wenjie Xu Ph.D,
This virtual conference allows you to participate in a global setting with no travel or cost to you. You can participate in exactly those parts which you are interested in and be back at your desk or bench in an instant. Virtual events remove time and place restrictions and ensure that everyone who wants to participate can do so. This virtual conference also offers increased reach for the global microbiology community with a high degree of interaction through live-streaming video and chat sessions.
Webinar Live during: Sep 08, 2016 at 7:30am
by Patrick Danaher, Ph.D., ,
For many researchers, understanding analytical results can be a major bottleneck to productivity, especially as data sets increase in size and complexity. In this 30-minute webinar, learn how to explore your own digital, multiplexed data with the nCounter Advanced Analysis plugin for nSolver. Examine experimental trends, identify pathway- specific responses, and profile immune cell populations independently and efficiently with our included software tools.
6:00am PST (Seattle)
9:00am PST (Seattle)
2:00pm BST (England, Scotland)
3:00pm CEST (Germany)
5:00pm BST (England, Scotland)
6:00pm CEST (Germany)
7:30am India Standard Time
10:00am China Standard Time
Webinar Live during: Aug 31, 2016 at 6:00am
Pages: 1 2 3 NEXT
by Wenjie Xu, Technical Services Scientist
Learn how nCounter® technology can advance your infectious disease research faster and more accurately with unprecedented sensitivity, reproducibility and ease of use. nCounter has been successfully used for identification and profiling of viruses, bacteria and fungi from real life infection samples. One single RNA isolation can generate paired data for both pathogen and host. Thanks to the automated and streamlined workflow, it takes less than 48 hours from sample collection to publication grade figures.
6:00 AM PST
9:00 AM PST
2:00 PM BST (London)
3:00 PM CEST (Germany, France)
7:30 AM IST (India)
10:00 AM CST (Beijing)
Webinar Live during: Jul 27, 2016 at 6:00am
by Jana Jandova , Ph.D
Join us and learn about recent studies that have shown for the first time that NanoString nCounter PanCancer panel is suitable to access the expression profiling of FFPE samples. As early-onset CRC tumors mostly available in FFPE format, this approach will enable to analyze larget cohorts of especially early-onset CRC patients and help find novel molecular signatures characteristic to early-onset CRC and better understand the etiology of this unfortunate disease.
Webinar Live during: Jul 20, 2016 at 9:00am
by Yvonne Saenger MD,
Biomarker development for melanoma has been limited by the challenge of isolating high-quality RNA for transcriptome-wide profiling from formalin-fixed and paraffin-embedded (FFPE) primary tumor specimens. Using NanoString technology, RNA from 40 stage II-III FFPE primary melanomas was analyzed and a 53-immune-gene panel predictive of non-progression (area under the curve (AUC)=0.920) was defined. The signature predicted disease-specific survival (DSS P
Webinar Live during: Jul 13, 2016 at 9:00am
by Patrick Danaher, Ph.D., , Senior Biostatistician
The long-touted field of gene expression diagnostics is finally hitting its stride, seeing a flurry of development activity and a trend of increasing acceptance from regulators, payers and doctors. This webinar, the second in our three-part series on Biomarker Discovery and Signature Development, will provide an in-depth view of GX signature development. We will start by discussing current trends in the field of gene expression diagnostics followed by a comprehensive view of the approaches that have led to successful signature development. Finally, we will explore the powerful strategies and pitfalls in the training of gene expression signature development.
Broadcast 1: 8 July, 2016
6:00 AM PST (USA)
2:00 PM BST / 3:00 PM CEST (UK/Europe)
- - - - - - - - - -
Broadcast 2: 8 July, 2016
9:00 AM PST (USA)
5:00 PM BST / 6:00 PM CEST (UK/Europe)
- - - - - - - - - -
Broadcast 3: Asia/Pacific
11 July, 2016
7:30 AM IST / 10:00 AM CST
Please join Patrick Danaher, Senior Biostatistician with NanoString Technologies for "Gene Expression Signature Development: The Discovery Phase; State of the Field and Lessons Learned," as part of our Biomarkers Webinar Series.
Webinar Live during: Jul 11, 2016 at 7:30am
by Rich Boykin , Director of Bioinformatics
NanoString’s Gene Fusion Panels provide a highly-multiplexed assay capable of simultaneously characterizing key fusion events and selected reference genes in a single tube. This webinar will discuss the design and development of assays for detection of Lung and Leukemia fusion genes.
10:00 AM (Beijing, Hong Kong)
7:30 AM (Sri Lanka)
2:00 PM UK
Webinar Live during: Jun 27, 2016 at 6:00am
by Kirsteen Maclean , Sr. Field Application Scientist
Recent studies have shown that changes in miRNA can be correlated with gene expression changes in development, differentiation, signla transduction, infection, aging, and disease. Biomarker discovery of miRNA
Join the webinar and learn about NanoString’s nCounter® miRNA assay, applications such as biomarker discovery and signature development, data from various sample types, and capability of performing one assay for both miRNA and mRNA from the same sample.
6am PST (Seattle)
9am PST (Seattle)
2pm BST (England, Scotland) / 3pm CEST
5pm BST (England, Scotland) / 6pm CEST
Webinar Live during: Jun 21, 2016 at 6:00am
by Wesley H. Buckingham , Manager, Dx Development
Gene expression signatures are emerging as important prognostic and predictive tools for the treatment of cancer. The presentation will discuss best practices for development and validation of gene expression signatures based on NanoString’s experience in developing IVD test kits.
6AM PST (Seattle)
2PM BST (England, Scotland)
3PM CEST (Germany)
9AM PST (Seattle)
5PM BST (England, Scotland)
6PM CEST (Germany)
Webinar Live during: Jun 13, 2016 at 6:00am
by Gavin Meredith & Niro Ramachandran,
With the growth of biomarker discovery, identification of novel cancer signatures has revealed the limitations of relying on a single analyte class to characterize tumors or predict their responses to therapies. NanoString has developed its novel 3D Biology™ technology and its Vantage™ line of products to meet the need for simultaneous analysis of DNA, RNA, and proteins.
Webinar Live during: May 25, 2016 at 9:00am
Pages: PREV 1 2 3 NEXT
by Joseph Beechem Ph.D & Alessandra Cesano MD, Ph.D,
The ability to measure changes to DNA, RNA, and protein across cell types is crucial to understanding the immune response to the environment or therapeutic treatment. NanoString Technologies has pioneered the concept of 3D Biology: the ability to measure DNA, RNA, and protein simultaneously using a single detector from a small sample, allowing precise characterization of these complex interactions.
Webinar Live during: May 17, 2016 at 9:00am
by Joseph M. Beechem, Ph.D.
Learn how the nCounter SPRINT™ Profiler can benefit your RNA, DNA, and protein profiling applications Speakers: Joseph M. Beechem Ph.D., Sr. VP of Research & Development | NanoString Technologies & Keith Farnsworth, Director of Product Management | NanoString Technologies
Webinar Live during: Aug 01, 2015
by Patrick Danaher,
This Webinar is sponsored by NanoString
Webinar Live during: Feb 21, 2012 at 1:00am
Pages: PREV 1 2 3 NEXT
by Christine Hipsky, NanoString and Kai Kleiber, Nanostring, Applications Scientist & Inside Sales Representative
The ability to measure changes to DNA, RNA, and protein is crucial to developing a comprehensive understanding of biology in the genomics era. NanoString Technologies has developed the nCounter® Analysis System for use in high-resolution multi-parameter analysis of biomolecules – the ability to measure any combination of DNA, RNA, and protein simultaneously using a single detector from a sample of limited volume and concentration.
Please join us for a webinar spotlighting 3D Biology™ Technology: Multiplexed Digital Quantification of RNA, DNA, & Proteins. Please register using the form to the right:
Webinar Live during: ,